Japanese drugmaker Ono Pharmaceutical (TYO: 4528) has received approval from South Korea’s Ministry of Food and Drug Safety (MFDS) for its New Drug Application for the human anti-human PD-1 monoclonal antibody Opdivo (nivolumab) for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab (Yervoy) and, if BRAF V600E mutation positive, a BRAF inhibitor.
Ono, which is co-developing Opdivo under license from US pharma major Bristol-Myers Squibb (NYSE: BMY), will manufacture its finished product (vial product) and supply it to Ono Pharma Korea (OPKR).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze